Market Access as a Commercial Strategy Discipline: What Nineteen Launches Taught Me About the Payer Conversation
This is the fifth and final post in a five-part series — What 19 Product Launches Taught Me.
Post 1:What 19 Product Launches Taught Me
Post 2: Know Your Customer Better Than They Know Themselves
Post 3: The Price Is The Strategy
Post 4: Getting Through the Noise
Market access is not a commercial function. It is a commercial condition.
A product without market access is not commercially available — regardless of how compelling its clinical profile is, how precisely it is priced, how well its stakeholders are segmented and targeted, or how effectively its communication strategy reaches and persuades the prescribers who want to use it. If the payer does not cover it, if the formulary committee has not placed it, if the prior authorization requirements create a friction that neither the physician nor the patient will absorb — the product is clinically available and commercially absent. The distinction between those two states is the entirety of what market access means in practice.
The US healthcare system is the most complex commercial channel in the world. It is not a single market but a layered architecture of payers, formularies, benefit designs, channel economics, clinical evidence standards, and regulatory requirements — varying by geography, by product category, by indication, and by the specific buying center involved in each coverage decision. Understanding that architecture — its logic, its incentives, and the relationships that make it navigable — is not optional for a life sciences commercial leader. It is foundational.
Nineteen product launches across five therapy sectors produced a consistent lesson: the organizations that built their market access strategy alongside their clinical and commercial strategy — treating it as an input to development decisions, not a post-approval problem to solve — consistently achieved broader access, faster formulary placement, and more durable reimbursement than the organizations that arrived at approval without it.
Market access is the gate through which a product's clinical profile, pricing strategy, and communication architecture must pass before any of it reaches the patient. Organizations that build this gate after approval find themselves unlocking a door that should have been designed open from the start.
The Payer Landscape: Who Controls Access and Why
The payer landscape in US healthcare is not monolithic. It is composed of distinct segments with different coverage philosophies, different evidence requirements, and different contracting structures — and the market access strategy must be calibrated to each one separately.
Commercial payers — employer-sponsored and individual health plans managed by national and regional insurers — represent the largest share of covered lives for most specialty pharmaceutical and biologic products. Commercial formulary decisions are made by Pharmacy and Therapeutics (P&T) committees whose deliberations are informed by clinical evidence, health economics data, and competitive contracting. The key commercial relationship is with the medical or pharmacy director who chairs or advises the P&T committee — a relationship built through scientific exchange and outcomes data, not promotional messaging.
Medicare and Medicaid — the two largest government payers, each with distinct coverage and reimbursement mechanisms. Medicare Part B covers physician-administered products under the medical benefit — reimbursed at Average Sales Price (ASP) plus a percentage margin. Medicare Part D covers patient-dispensed products under the pharmacy benefit — reimbursed through formulary contracting with Pharmacy Benefit Managers (PBMs). Medicaid coverage varies by state, managed through state-specific formularies and supplemental rebate agreements. For many specialty products, government payer access is structurally different from commercial access and requires a dedicated strategy.
Integrated Delivery Networks and health systems — are increasingly functioning as de facto payers — making formulary and procurement decisions that determine which products are available to their employed physicians and their contracted patient populations. The IDN's pharmacy and therapeutics process mirrors the commercial payer's, but the contracting relationship is direct with the health system rather than mediated by a PBM or managed care organization. Health system relationships — with the Chief Medical Officer, the pharmacy director, the value analysis committee — are among the most strategically important relationships a life sciences commercial organization can build before launch.
The Gross-to-Net Waterfall: What the Product Actually Earns
The list price a manufacturer sets is not the price any participant in the US healthcare channel actually pays. Between the list price and the net revenue the organization receives, a series of discounts, rebates, fees, and patient assistance expenditures reduce the effective price at every layer of the distribution chain.
The gross-to-net waterfall — the cascade from list price to net realized price — includes wholesaler distribution fees, Group Purchasing Organization (GPO) contract discounts, commercial payer rebates negotiated for formulary placement, Medicaid best-price calculations, 340B program pricing for qualifying health systems, and patient copay assistance programs that reduce the patient's out-of-pocket cost to drive adherence. Each element of this waterfall is a commercial decision with revenue implications that compound across the product's volume.
The commercial implication is significant: the list price communicates to the market, but the net price determines the economics of the commercial model. An organization that sets list price without modeling the gross-to-net waterfall across its payer mix may find that the revenue its commercial model requires is not achievable at the net prices the contracting environment will produce. This analysis must be completed before the list price is set — and it must be updated as the payer mix shifts through the product's commercial life.
The list price communicates to the market. The net price determines the economics of the commercial model. These are different numbers — and the gap between them must be understood before the first price is set.
Three Channels, Three Market Access Realities
The channel through which a product reaches the patient determines the market access architecture the commercial strategy must navigate. The three primary channel pathways in life sciences each create a distinct coverage and reimbursement environment with distinct commercial implications.
Buy-and-bill — the physician or hospital purchases the product, administers it, and bills the payer for the product and its administration under the medical benefit. Coverage is determined by the payer's medical policy — the clinical criteria under which the product is covered for specific indications and patient populations. Reimbursement is calculated at ASP plus a margin for Medicare Part B, and at contracted rates for commercial payers. The commercial strategy must secure favorable medical policy coverage and sufficient reimbursement spread to make the product economically viable for the physicians and facilities administering it. A product that is clinically preferred but economically disadvantageous within the buy-and-bill model will not achieve the utilization its clinical profile merits.
Specialty pharmacy distribution — the product is dispensed directly to the patient through a specialty pharmacy under the pharmacy benefit. Coverage is determined by the payer's formulary tier and the PBM's utilization management protocols — prior authorization requirements, step therapy mandates, quantity limits, and specialty tier cost-sharing. The commercial strategy must secure favorable formulary placement — ideally preferred tier status without restrictive PA criteria — through contracting with the major PBMs and regional health plan formularies. Pull-through strategy — ensuring that prescriptions written successfully navigate the PA process and reach patients without abandonment — is a distinct and ongoing commercial challenge that begins at the point of formulary placement, not at the point of prescribing.
Diagnostic and laboratory channels — the product is a test or diagnostic platform performed by a laboratory and reimbursed under a professional fee or technical fee model. Coverage is determined by the payer's medical policy for the specific diagnostic code, and reimbursement is set by CMS through the Clinical Laboratory Fee Schedule (CLFS) or through local coverage determinations (LCDs) by the Medicare Administrative Contractors. Commercial payer coverage often follows Medicare — making the CMS coverage determination the most consequential single market access event for a diagnostic product. The commercial strategy must build the clinical and economic evidence case for coverage before the CMS coverage process is initiated, not in response to it.
The Formulary Decision: How Access Is Won and What It Costs to Maintain
Formulary placement is the operational outcome of the market access strategy — the decision by a payer's Pharmacy and Therapeutics committee that a product will be covered, at what tier, and under what clinical management criteria. Winning favorable formulary placement requires the convergence of clinical evidence, health economics evidence, competitive contracting, and organizational relationships — each of which takes time to build and none of which can be fully constructed after approval.
The P&T committee's deliberation is informed by a systematic review of the product's clinical dossier — efficacy, safety, and comparative effectiveness against existing alternatives — and by the health economics submission, which makes the case for the product's value relative to its cost. The health economics argument is where the True Economic Value framework from Post 3 of this series becomes most directly relevant: the payer's question is not whether the product works, but whether it works well enough, in the right patient population, to justify its cost relative to every other treatment option on the formulary.
Prior authorization, step therapy, and quantity limit restrictions are the instruments through which payers manage utilization for products placed on the formulary. Each restriction creates friction between the prescribing decision and the patient receiving the product — friction that reduces effective utilization, increases physician administrative burden, and degrades the patient experience. The commercial strategy must anticipate these restrictions, generate the clinical and economic evidence to justify their removal over time, and deploy patient support infrastructure to help patients navigate the access barriers that cannot be immediately eliminated.
Market Access Is a Commercial Strategy Discipline, Not a Function
The single most important lesson nineteen launches taught about market access is this: the organizations that treated it as a commercial strategy discipline — integrated into the development plan, the evidence generation strategy, the pricing architecture, and the communication investment from the earliest possible stage — consistently achieved outcomes that post-approval market access efforts could not replicate.
The clinical trial design choices made in Phase II determine the evidence the payer will have available to make a coverage decision. The value proposition built around the patient population most likely to benefit determines how narrow or broad that coverage will be. The health economics model built before Phase III determines whether the HEOR evidence generated in the pivotal trials will be sufficient to make the economic case to a skeptical formulary committee. The payer relationships built before launch determine whether the coverage decision is made with the benefit of the organization's perspective or against it.
Each of these is a development decision, not a launch decision. An organization that waits until approval to think about market access finds itself trying to build the evidentiary case for a product whose trial design, patient population, and comparator selection were not optimized for the payer audience. It is the commercial equivalent of designing a product for the wrong customer — and discovering the mismatch after the manufacturing line is already running.
The relationship capital required to navigate the US healthcare system's complexity — with medical directors, pharmacy directors, health system formulary committees, specialty pharmacy networks, and patient advocacy organizations — is built over years, not months. It is the most durable commercial asset in life sciences, and the most difficult to accelerate when it has not been built in advance.
The organizations that treated market access as a commercial strategy discipline — integrated into development decisions from the earliest stage — consistently achieved outcomes that post-approval market access efforts could not replicate.
Closing the Series: What the Field Actually Teaches
Five posts. Five frameworks. Nineteen launches across five therapy sectors. The frameworks change by domain — segmentation and positioning look different from pricing, which looks different from communication, which looks different from market access. What does not change is the underlying principle that connects all five.
Commercial success in life sciences is not a function of product quality. It is a function of how well an organization understands, reaches, and creates value for every stakeholder in the adoption ecosystem — before any competitor does, and before the market has decided who wins. The frameworks in this series are the analytical tools that make that understanding systematic, that make the commercial decisions defensible, and that make the execution accountable.
What the field teaches that the frameworks alone cannot: every stakeholder is a person. The payer medical director making the formulary decision has professional obligations, institutional constraints, and evidentiary standards that a well-built health economics model must speak to honestly — not manipulate. The physician weighing a prescribing decision has patient obligations and practice economics that the value proposition must address genuinely — not overstate. The patient navigating a prior authorization process has a health condition that the access infrastructure must help them manage — not abandon to the complexity of the system.
The commercial leader who holds all of this simultaneously — the analytical rigor of the frameworks and the human reality of the stakeholders they describe — is the leader this industry needs and consistently underproduces. Building the case for that leader, and demonstrating what they look like in practice, is what this series has been about.
The frameworks are tools for understanding people. The commercial leader who holds the analytical rigor of the frameworks and the human reality of the stakeholders they describe is the leader this industry needs and consistently underproduces.
The Complete Series
Post 1: What 19 Product Launches Taught Me: A Field Guide to Commercial Viability
Post 2: Know Your Customer Better Than They Know Themselves
Post 3: The Price Is the Strategy
Post 4: Getting Through the Noise
Post 5: Market Access as a Commercial Strategy Discipline — You are here — final post in the series.
